NCT00005598View on ClinicalTrials.gov

Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

October 31, 2000

Primary Completion Date

December 31, 2001

Study Completion Date

March 31, 2002

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

amifostine trihydrate

DRUG

azacitidine

Trial Locations (1)

48109-0752

University of Michigan Comprehensive Cancer Center, Ann Arbor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Michigan Rogel Cancer Center

OTHER

NCT00005598 - Azacitidine Plus Amifostine in Treating Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter